Singapore’s Oligonucleotide Synthesis Market, valued at US$ XX billion in 2024 and 2025, is expected to grow steadily at a CAGR of XX% from 2025–2030, reaching US$ XX billion by 2030.
Global oligonucleotide synthesis market valued at $8.9B in 2024, reached $10.5B in 2025, and is projected to grow at a robust 18.6% CAGR, hitting $ 24.7B by 2030.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350
Drivers
The Singapore Oligonucleotide Synthesis Market is strongly driven by the nation’s aggressive push into R&D and advanced biomanufacturing, positioning itself as a leading biomedical hub in Asia. A primary driver is the accelerating use of synthetic oligonucleotides in the development of novel nucleic acid-based therapeutics, including Antisense Oligonucleotides (ASOs), small interfering RNAs (siRNAs), and mRNA vaccines. Singapore provides substantial government funding and institutional support through agencies like the Agency for Science, Technology and Research (A*STAR) to bolster these areas. The high incidence of chronic and genetic diseases locally and regionally also increases the demand for targeted therapies and personalized medicine, where oligonucleotides are crucial for diagnostics and drug development. Furthermore, Singapore’s stringent intellectual property protection laws and its established ecosystem of global pharmaceutical and biotechnology companies make it an attractive location for high-value synthesis and manufacturing operations. The growing academic research in genomics, proteomics, and synthetic biology further contributes to market momentum by requiring custom and high-quality synthetic oligos for foundational research, driving continuous demand from universities and research institutions.
Restraints
Several restraints impede the growth of Singapore’s Oligonucleotide Synthesis Market, predominantly related to the high complexity and cost associated with large-scale production. The chemical synthesis process for oligonucleotides is intricate and requires specialized equipment, high-purity reagents, and stringent quality control, which results in high manufacturing costs compared to conventional small-molecule drug production. Technical challenges, such as the difficulty in synthesizing long and complex oligonucleotide strands with high fidelity and yield, remain a significant bottleneck. Moreover, purifying and stabilizing these molecules, particularly for therapeutic use, poses significant hurdles that impact scalability and commercial viability. The regulatory landscape, while robust, can be complex and time-consuming for novel oligonucleotide-based drug candidates, slowing down market access. Lastly, the industry faces a shortage of highly specialized scientific and engineering talent with expertise in both chemistry and large-scale cGMP oligonucleotide manufacturing, creating a dependency on international expertise and driving up labor costs, thereby restraining rapid market expansion.
Opportunities
Significant opportunities exist for the Singapore Oligonucleotide Synthesis Market, centered on leveraging its strong position in advanced manufacturing and healthcare. The most prominent opportunity lies in capitalizing on the global shift toward mRNA vaccine and therapeutic manufacturing capacity, where oligonucleotides are key starting materials. Singapore can strategically position itself as a regional hub for contract synthesis and manufacturing of these critical components. Another major opportunity is the rapid expansion of gene therapy and cell therapy, which rely heavily on high-quality synthetic nucleic acids for research and clinical applications, including CRISPR/Cas9 systems. Strategic public-private partnerships, particularly between local academic institutions and multinational biopharma companies, can accelerate the commercialization of new synthesis technologies and high-throughput production methods. Furthermore, expanding applications into non-therapeutic fields such as advanced diagnostics, synthetic biology, and industrial biotechnology offers diversified revenue potential. Focused investment in automation and miniaturization of synthesis equipment will also reduce production costs, making oligonucleotide synthesis more accessible for smaller research groups and boosting the market size.
Challenges
The Singapore Oligonucleotide Synthesis Market must overcome several challenges to maintain its competitive advantage. The foremost challenge is addressing the scalability gap between small-scale R&D synthesis and industrial-scale cGMP manufacturing required for clinical trials and commercial production. Scaling up production often involves substantial capital expenditure for facilities and sophisticated automated systems. A crucial technical challenge involves improving the chemical efficiency and reliability of synthesizing ultra-long oligonucleotide sequences needed for complex gene assembly and advanced therapeutics, minimizing truncated sequences and impurities. Intense global competition, particularly from established synthesis providers in North America and Europe, exerts constant pricing pressure. Furthermore, maintaining a highly skilled workforce proficient in the nuances of oligonucleotide chemistry, analytics, and quality assurance remains a persistent challenge that requires continuous investment in specialized training and education. Finally, ensuring the effective and targeted delivery of oligonucleotide-based drugs within the human body requires novel drug delivery system research, a challenge that directly impacts the downstream demand for synthesized oligos in therapeutic development.
Role of AI
Artificial Intelligence (AI) is set to revolutionize Singapore’s Oligonucleotide Synthesis Market by enhancing efficiency and accelerating therapeutic development. AI algorithms can be deployed to optimize the chemical synthesis process by predicting optimal reaction conditions, reagent ratios, and purification parameters, thereby increasing yield and purity while reducing production waste and cost. Machine learning models are vital for quality control, capable of rapidly analyzing complex mass spectrometry and sequencing data to detect minute impurities or synthesis errors far more accurately than manual methods. Furthermore, AI plays a crucial role in the design of novel oligonucleotide sequences for therapeutic applications, such as Antisense Oligonucleotides or siRNAs, by predicting their target binding affinity, off-target effects, and stability in biological systems, which dramatically speeds up the pre-clinical phase. Singapore’s existing commitment to smart manufacturing and digital health provides a fertile environment for integrating AI-driven automation into oligonucleotide production lines, moving towards fully autonomous “Oligo-Factories.” This synergy between advanced synthesis technology and predictive AI capabilities will be key to Singapore unlocking high-throughput, personalized oligonucleotide manufacturing.
Latest Trends
The Singapore Oligonucleotide Synthesis Market is currently shaped by several important trends focused on innovation and efficiency. A key trend is the maturation and adoption of enzymatic oligonucleotide synthesis (EOS), which offers a greener, faster alternative to traditional phosphoramidite chemistry, with the potential for synthesizing longer and more complex DNA/RNA strands. This trend is gaining traction in Singapore’s biotech R&D circles due to its sustainability and scalability benefits. Another trend is the growing demand for highly modified oligonucleotides, incorporating specialized chemistries (like LNA, 2′-O-methyl) to improve stability, target specificity, and cell penetration for next-generation therapeutics. The market is also seeing a shift towards increased automation and miniaturization of synthesis platforms, often integrated with microfluidics, enabling faster turnaround times for custom synthesis services and supporting high-throughput screening applications. Furthermore, there is a distinct trend towards vertical integration, where synthesis providers are expanding their service offerings to include downstream processing such as formulation and cGMP manufacturing, creating comprehensive “sequence-to-drug” solutions, which is vital for Singapore’s biopharma contract service providers. Lastly, the adoption of digital quality assurance and blockchain technology for supply chain traceability is emerging as a critical trend to ensure the integrity and security of synthesized materials for therapeutic use.